Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Galectin Therapeutic (GALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,702
  • Shares Outstanding, K 35,640
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,440 K
  • 36-Month Beta 2.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.20 +39.77%
on 11/02/17
3.14 -2.07%
on 11/20/17
+0.41 (+15.60%)
since 10/20/17
3-Month
1.63 +88.65%
on 09/15/17
3.14 -2.07%
on 11/20/17
+1.35 (+77.75%)
since 08/21/17
52-Week
0.81 +279.63%
on 11/30/16
3.68 -16.44%
on 04/10/17
+2.11 (+217.01%)
since 11/21/16

Most Recent Stories

More News
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D., the Company's chief executive officer and chief medical...

GALT : 3.09 (+1.31%)
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced the presentation of preclinical and early...

GALT : 3.09 (+1.31%)
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update

All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial

GALT : 3.09 (+1.31%)
Galectin Therapeutics to Present Clinical Data at The Liver Meeting(R) 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj Vuppalanchi of Indiana University will present a poster demonstrating...

GALT : 3.09 (+1.31%)
Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher

Galectin Therapeutics, Inc. (GALT) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.

GALT : 3.09 (+1.31%)
MEIP : 2.15 (+0.94%)
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the Company's chief executive officer and chief medical officer...

GALT : 3.09 (+1.31%)
Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received a Decision to Grant from the Chinese Patent...

GALT : 3.09 (+1.31%)
Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the Rodman & Renshaw 19th Annual Global Investment...

GALT : 3.09 (+1.31%)
Earnings Review and Free Research Report: Zoetis' Results Beat Estimates in EPS and Revenues; Updated Full Year Guidance

Research Desk Line-up: Galectin Therapeutics Post Earnings Coverage

GALT : 3.09 (+1.31%)
ZTS : 71.46 (+0.72%)
Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Method...

GALT : 3.09 (+1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Key Turning Points

2nd Resistance Point 3.20
1st Resistance Point 3.13
Last Price 3.09
1st Support Level 2.99
2nd Support Level 2.92

See More

52-Week High 3.68
Last Price 3.09
Fibonacci 61.8% 2.58
Fibonacci 50% 2.25
Fibonacci 38.2% 1.91
52-Week Low 0.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart